Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01190306 · ClinicalTrials.gov registry record · Phase 3
Safety Study of the VEGA UV-A System to Treat Keratoconus
A Phase 3 study, sponsored by Topcon Medical Systems.
- Terminated
- Registry status
- Phase 3
- Development phase
- 127
- Enrollment target
NCT01190306: Clinical Trial Phase 3 study, sponsored by Topcon Medical Systems.
NCT01190306 is a Phase 3 study that was terminated before completion, run by Topcon Medical Systems. The registered enrollment target is 127 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01190306, a Phase 3 study, was terminated before completion, sponsored by Topcon Medical Systems.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.
Interventions
- DRUG Riboflavin
- DEVICE The VEGA UV-A Illumination System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01190306
The ClinicalTrials.gov registry entry for NCT01190306 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Topcon Medical Systems, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Riboflavin is the first listed.
NCT01190306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01190306 about?
NCT01190306 is a clinical study titled "Safety Study of the VEGA UV-A System to Treat Keratoconus". The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.
What is the current status of trial NCT01190306?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 2010-08. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01190306?
The interventions under investigation include: Riboflavin (DRUG), The VEGA UV-A Illumination System (DEVICE).
Who is sponsoring clinical trial NCT01190306?
This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.